Locus 135: APOE (19q13.32)
| Meta-analysis summary statistics for associations meeting genome-wide significance |
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs445925 |
X-11820 / cholesterol |
A/G |
5510 |
0.08 |
0.089 (0.009) |
4.65·10-23 |
show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs445925 |
| Chromosomal location | Chr19: 50,107,480 (19q13.32) |
| Gene (distance) | APOE (2,991) |
| Predicted causal gene | APOE|APOC1|APOC2 |
| Gene/protein classification | - |
| Metabolite (Pathway) | X-11820 (Unknown) cholesterol (Sterol, Steroid; Lipid) |
| Biochemical locus-metabolite relationship | APOE|APOC1|APOC2 locus has been associated with LDL, HDL and total cholesterol levels in previous GWAS [20686565]. Ratio interpretation: n/a. |
| eQTL associations | APOE (F), APOE (S), APOC2 (L) † |
† F = adipose tissue; S = skin cells; L = lymphoblastoid cells; H = liver cells;
| Medical information |
| Complex trait associations | Apolipoprotein Levels [23031429]; Cardiovascular disease risk factors [20838585]; Carotid intima media thickness [21909108]; Lipoprotein-associated phospholipase A2 activity and mass [23118302] |
| Known metabolite associations | Metabolite levels [22916037] |
| Inborn error of metabolism | Hyperlipidemia type 3 |
| Pharmacological information |
| ChEMBL ID | - |
| Drug information |
-
|
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

